Cost-Effectiveness Analysis of Rabeprazole versus Lansoprazole for Peptic Ulcer
- VernacularTitle:雷贝拉唑与兰索拉唑2种用药方案治疗消化性溃疡的成本-效果分析
- Author:
Shuangping JIN
;
Jingbo PEI
- Publication Type:Journal Article
- Keywords:
Pharmacoeconomics;
Peptic ulcer;
Rabeprazole;
Lansoprazole
- From:
China Pharmacy
1991;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To evaluate the cost-effectiveness of Rabeprazole versus Lansoprazole for peptic ulcer. METHODS: A total of 101 patients with peptic ulcer were randomly assigned to receive either Rabeprazole+Clarithromycin sustained release capsules+tinidazole(treatment group) or Lansoprazole+Clarithromycin sustained release capsules+tinidazole(control group) for 14 days. RESULTS: In the treatment group vs. the control group, the effective rate was 96.0% vs. 84.3%(P0.05); the cost was 285.46 vs. 373.87 yuan; the cost-effectiveness ratio was 297.35 vs. 443.50. The incremental cost-effectiveness ratio for the control group was -755.64 as against the treatment group. CONCLUSION: Rabeprazole group is optimal for peptic ulcer in that it is more economical, more effective and safer than Lansoprazole group.
